EICHORCondition: Angelman Syndrome · Sponsor: Ultragenyx Pharmaceutical Inc
The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman Syndrome (AS)
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of California, Los Angeles (UCLA) | Los Angeles, California, United States | — |
| University of California, San Diego - Rady Children's Hospital | San Diego, California, United States | — |
| Rare Disease Research, LLC | Atlanta, Georgia, United States | — |
| Rush University Medical Center | Chicago, Illinois, United States | — |
| Boston Children's Hospital | Boston, Massachusetts, United States | — |
| Weill Cornell Medicine | New York, New York, United States | — |
| Queensland Children's Hospital | South Brisbane, Queensland, Australia | — |
| The Royal Children's Hospital | Melbourne, Victoria, Australia | — |
| MAGIC Clinic Ltd | Calgary, Alberta, Canada | — |
| British Columbia Children's Hospital | Vancouver, British Columbia, Canada | — |
| Childrens Hospital London Health Sciences Centre | London, Ontario, Canada | — |
| Childrens Hospital of Eastern Ontario | Ottawa, Ontario, Canada | — |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06415344